Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS

Technology in Cancer Research and Treatment

Volumn 8, Issue 5, 2009, Pages 323-332

  Hegmans, Joost P J J ^a   Veltman, Joris D ^a   Fung, Eric T ^b   Verch, Thorsten ^c   Glover, Curtis ^c   Zhang, Fujun ^b   Allard, W Jeffrey ^c   T'Jampens, Davy ^b   Hoogsteden, Henk C ^a   Lambrecht, Bart N ^a   Aerts, Joachim ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

^c FUJIREBIO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; BIOLOGICAL MARKER; CYTOKERATIN 19; HUMAN EPIDIDYMES PROTEIN 4; ONCOPROTEIN; OSTEOPONTIN; SOLUBLE MESOTHELIN RELATED PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANION EXCHANGE CHROMATOGRAPHY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN C-I; AREA UNDER CURVE; FEMALE; HUMANS; IMMUNOASSAY; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEOME; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 70349335493     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460900800502     Document Type: Article

References (39)

1. Robinson, B. W., Musk, A. W., Lake, R. A. Malignant mesothelioma. Lancet 366(9483), 397-408 (2005).
2. Suster, S., Moran, C. A. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol 13(6), 316-329 (2006). (Pubitemid 44673447)
3. King, J. E., Thatcher, N., Pickering, C. A., Hasleton, P. S. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 48(3), 223-232 (2006).
4. Whitaker, D. The cytology of malignant mesothelioma. Cytopathology 11(3), 139-151 (2000).
5. Cagle, P. T., Churg, A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 129(11), 1421-1427 (2005). (Pubitemid 41587017)
6. Pass, H. I., Lott, D., Lonardo, F., Harbut, M., Liu, Z., Tang, N., et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353(15), 1564-1573 (2005). (Pubitemid 41434635)
7. Hassan, R., Remaley, A. T., Sampson, M. L., Zhang, J., Cox, D. D., Pingpank, J., et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12(2), 447-453 (2006). (Pubitemid 43166134)
8. Robinson, B. W., Creaney, J., Lake, R., Nowak, A., Musk, A. W., de Klerk, N., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362(9396), 1612-1616 (2003).
9. Gilbert, K., Figueredo, S., Meng, X. Y., Yip, C., Fung, E. T. Serum protein-expression profiling using the ProteinChip biomarker system. Methods Mol Biol 264, 259-269 (2004).
10. Tibshirani, R., Hastie, T., Narasimhan, B., Chu, G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99(10), 6567-6572 (2002). (Pubitemid 34526173)
11. Hothorn, T. L. B. On the exact distribution of maximally selected rank statistics. Computional Statistics & Data Analysis 43, 121-137 (2003).
12. Engwegen, J. Y., Helgason, H. H., Cats, A., Harris, N., Bonfrer, J. M., Schellens, J. H., et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 12(10), 1536-1544 (2006).
13. Scherpereel, A., Lee, Y. G. Biomarkers for mesothelioma. Curr Opin Pulm Med 13(4), 339-443 (2007).
14. Hortin, G. L. R. A.T. Mass determination of major plasma proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Proteomics 2(1-2), 103-115 (2007).
15. Rossi, L., Martin, B. M., Hortin, G. L., White, R. L., Foster, M., Moharram, R., et al. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 6(2), 709-720 (2006). (Pubitemid 43208049)
16. Goncalves, A., Esterni, B., Bertucci, F., Sauvan, R., Chabannon, C., Cubizolles, M., et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25(7), 981-989 (2006). (Pubitemid 43277006)
17. Galgano, M. T., Hampton, G. M., Frierson, H. F., Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19(6), 847-853 (2006).
18. Drapkin, R., von Horsten, H. H., Lin, Y., Mok, S. C., Crum, C. P., Welch, W. R., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65(6), 2162-2169 (2005). (Pubitemid 40490123)
19. Bingle, L., Cross, S. S., High, A. S., Wallace, W. A., Rassl. D., Yuan, G., et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 7(61), (2006).
20. Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, K., Perruzzi, C. A., et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 145(3), 610-623 (1994). (Pubitemid 24285968)
21. Saitoh, Y., Kuratsu, J., Takeshima, H., Yamamoto, S., Ushio, Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 72(1), 55-63 (1995).
22. Bellahcene, A., Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146(1), 95-100 (1995).
23. Chambers, A. F., Wilson, S. M., Kerkvliet, N., O'Malley, F. P., Harris, J. F., Casson, A. G. Osteopontin expression in lung cancer. Lung Cancer 15(3), 311-323 (1996).
24. Thalmann, G. N., Sikes, R. A., Devoll, R. E., Kiefer, J. A., Markwalder, R., Klima, I., et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5(8), 2271-2277 (1999). (Pubitemid 29399287)
25. Zhang, J., Takahashi, K., Takahashi, F., Shimizu, K., Ohshita, F., Kameda, Y., et al. Differential osteopontin expression in lung cancer. Cancer Lett 171(2), 215-222 (2001). (Pubitemid 32772809)
26. Fedarko, N. S., Jain, A., Karadag, A., Van Eman, M. R., Fisher, L. W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7(12), 4060-4066 (2001). (Pubitemid 34044628)
27. O'Regan, A., Fleming, C. Osteopontin as a biomarker for ovarian cancer. Jama 287(24), 3208-9 (2002); author reply 3209-3210.
28. Marukawa, M., Hiyama, J., Shiota, Y., Ono, T., Sasaki, N., Taniyama, K., et al. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma. Acta Med Okayama 52(2), 119-123 (1998). (Pubitemid 128456897)
29. Paganuzzi, M., Onetto, M., Marroni, P., Filiberti, R., Tassara, E., Parodi, S., et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 119(4), 1138-1142 (2001). (Pubitemid 32679442)
30. Bonfrer, J. M., Schouwink, J. H., Korse, C. M., Baas, P. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 17(4B), 2971-2973 (1997). (Pubitemid 27434834)
31. Maeda, M., Hino, O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 56(11), 649-654 (2006). (Pubitemid 44570013)
32. Onda, M., Nagata, S., Ho, M., Bera, T. K., Hassan, R., Alexander, R. H., et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 12(14 Pt 1), 4225-4231 (2006).
33. Hellstrom, I., Raycraft, J., Kanan, S., Sardesai, N. Y., Verch, T., Yang, Y., et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 15(5), 1014-1020 (2006). (Pubitemid 43823532)
34. Kojima, T., Oh-eda, M., Hattori, K., Taniguchi, Y., Tamura, M., Ochi, N., et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 270(37), 21984-21990 (1995).
35. Scherpereel, A., Grigoriu, B., Conti, M., Gey, T., Gregoire, M., Copin, M. C., et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173(10), 1155-1160 (2006). (Pubitemid 43726897)
36. Creaney, J., Robinson, B. W. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 19(6), 1025-1040 (2005). (Pubitemid 41736040)
37. Robinson, B. W., Lake, R. A. Advances in malignant mesothelioma. N Engl J Med 353(15), 1591-1603 (2005).
38. Di Serio, F., Fontana, A., Loizzi, M., Capotorto, G., Maggiolini, P., Mera, E., et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 45(5), 634-638 (2007). (Pubitemid 46709735)
39. Beyer, H. L., Geschwindt, R. D., Glover, C. L., Tran, L., Hellstrom, I., Hellstrom, K. E., et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 53(4), 666-672 (2007). (Pubitemid 46580236)